A5039722353- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Global Cancer Incidence and Screening
- Cancer Treatment and Pharmacology
- Breast Lesions and Carcinomas
- Economic and Financial Impacts of Cancer
- BRCA gene mutations in cancer
- Cancer Diagnosis and Treatment
- Estrogen and related hormone effects
- Cancer Risks and Factors
- Chronic Lymphocytic Leukemia Research
- Cancer Genomics and Diagnostics
- Multiple and Secondary Primary Cancers
- Breast Implant and Reconstruction
- Bone health and treatments
- Health Systems, Economic Evaluations, Quality of Life
- PI3K/AKT/mTOR signaling in cancer
- Cancer-related Molecular Pathways
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Treatments and Mutations
- Gene expression and cancer classification
- Cancer survivorship and care
- Advances in Oncology and Radiotherapy
- Cancer-related cognitive impairment studies
The University of Texas MD Anderson Cancer Center
2016-2025
American Society of Clinical Oncology
2018-2024
The University of Texas Health Science Center at Houston
2017-2022
Samsung (United States)
2022
Pfizer (United States)
2022
Columbia University Irving Medical Center
2022
Massachusetts General Hospital
2016-2022
National Institutes of Health
2022
National Center for Advancing Translational Sciences
2022
Susan G. Komen Breast Cancer Foundation
2022
PURPOSE To update key recommendations of the American Society Clinical Oncology/College Pathologists estrogen (ER) and progesterone receptor (PgR) testing in breast cancer guideline. METHODS A multidisciplinary international Expert Panel was convened to clinical practice guideline informed by a systematic review medical literature. RECOMMENDATIONS The continues recommend ER invasive cancers validated immunohistochemistry as standard for predicting which patients may benefit from endocrine...
Purpose Placing clips in nodes with biopsy-confirmed metastasis before initiating neoadjuvant therapy allows for evaluation of response breast cancer. Our goal was to determine if pathologic changes clipped reflect the status nodal basin and targeted axillary dissection (TAD), which includes sentinel lymph node (SLND) selective localization removal nodes, improves false-negative rate (FNR) compared SLND alone. Methods A prospective study patients metastases a clip placed sampled performed....
To examine the association between beta-blocker (BB) intake, pathologic complete response (pCR) rates, and survival outcomes in patients with breast cancer treated neoadjuvant chemotherapy.We retrospectively reviewed 1,413 who received chemotherapy 1995 2007. Patients taking BBs at start of therapy were compared no BB intake. Rates pCR groups using a χ² test. Cox proportional hazards models fitted to determine relapse-free (RFS), overall (OS).Patients used (n = 102) 1,311) did not. receiving...
Adjuvant chemotherapy improves outcomes of patients with breast cancer. However, the optimal timing initiation is unknown. Delayed administration can decrease benefit cytotoxic systemic therapies.
Purpose.— To update key recommendations of the American Society Clinical Oncology/College Pathologists estrogen receptor (ER) and progesterone (PgR) testing in breast cancer guideline. Methods.— A multidisciplinary international Expert Panel was convened to clinical practice guideline informed by a systematic review medical literature. Recommendations.— The continues recommend ER invasive cancers validated immunohistochemistry as standard for predicting which patients may benefit from...
For patients with breast cancer (BC), the optimal time to initiation of adjuvant chemotherapy (TTC) after definitive surgery is unknown. We evaluated association between TTC and survival according subtype stage at diagnosis.Women diagnosed BC stages I III 1997 2011 who received our institution were included. Patients categorized into three groups TTC: ≤ 30, 31 60, ≥ 61 days. Survival outcomes estimated compared by subtype.Among 6,827 included, 5-year overall (OS), relapse-free (RFS), distant...
The use of trastuzumab in the adjuvant setting improves outcomes but is associated with cardiotoxicity manifested as congestive heart failure (CHF). rates and risk factors trastuzumab-related CHF among older patients are unknown.Breast cancer at least 66 years old full Medicare coverage, diagnosed stage I-III breast between 2005 2009, treated chemotherapy were identified SEER-Medicare Texas Cancer Registry-Medicare databases. evaluated. Chemotherapy, use, comorbidities, using International...
The PI3K/AKT pathway is activated through PIK3CA or AKT1 mutations and PTEN loss in breast cancer. We conducted a phase II trial with an allosteric AKT inhibitor MK-2206 patients advanced cancer who had tumors PIK3CA/AKT1 and/or loss/mutation. primary endpoint was objective response rate (ORR). Secondary endpoints were 6-month progression-free survival (6 m PFS), predictive pharmacodynamic markers, safety, tolerability. Patients pre-treatment on-treatment biopsies as well collection of...
As the COVID-19 pandemic continues, understanding clinical outcomes of patients with cancer and has become critically important.To compare or without who were diagnosed to identify factors associated mortality, mechanical ventilation, intensive care unit (ICU) stay, hospitalization.This cohort study obtained data from Optum de-identified electronic health record set. More than 500 000 US adults January 1 December 31, 2020, analyzed.The patient groups (1) cancer, (2) no recent treatment, (3)...
<h3>Importance</h3> The American Joint Committee on Cancer (AJCC) eighth edition staging manual introduced a new prognostic stage for breast cancer incorporating biologic factors in addition to traditional anatomic factors. <h3>Objective</h3> To perform validation study of the AJCC single-institution cohort and large population database. <h3>Design, Setting, Participants</h3> Patients with treated surgery as an initial intervention were identified prospective institutional database from...
To provide recommendations on the best strategies for management and timing treatment (surgical radiotherapeutic) of axilla patients with early-stage breast cancer.Ontario Health (Cancer Care Ontario) ASCO convened a Working Group Expert Panel to develop evidence-based informed by systematic review literature.This guideline endorsed two 2017 use sentinel lymph node biopsy in cancer expanded that radiotherapy interventions, staging after neoadjuvant chemotherapy (NAC), mapping modalities....
<h3>Importance</h3> Triple-negative breast cancer (TNBC) classified by transcriptional profiling as the mesenchymal subtype frequently harbors aberrations in phosphoinositide 3-kinase (PI3K) pathway, raising possibility of targeting this pathway to enhance chemotherapy response. Up 30% TNBC can be histologically metaplastic cancer, a chemorefractory group tumors with mixture epithelial and components identifiable light microscopy. While assays identify are under development, serves...
<h3>Importance</h3> Studies showing that patients with cancer from rural areas have worse outcomes than their urban counterparts relied on population data and did not account for differences in access to care. Clinical trial receive protocol-directed care by design, so large clinical databases are ideal examining the impact of vs residency outcomes. <h3>Objective</h3> To compare geographic distribution survival treated trials. <h3>Design, Setting, Participants</h3> In this comparative...
LBA1003 Background: PAL was the first cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved for ER+/HER2– ABC based on randomized, phase 2 PALOMA-1 study. PALOMA-2 is a double-blind, 3 trial in first-line that confirmed clinically and statistically significant improvement progression-free survival (PFS) with PAL+LET versus PBO+LET (median PFS, 27.6 vs 14.5 months; hazard ratio, 0.56 [95% CI, 0.46–0.69]; P<0.0001). At time of final PFS analysis, OS data were not mature. Herein, we report...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned coprimary or secondary analyses are not yet available. trial updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. PALOMA-2 demonstrated statistically and clinically significant improvement progression-free survival with...
This manuscript describes the Advanced Breast Cancer (ABC) international consensus guidelines updated at last two ABC conferences (ABC 6 in 2021, virtual, and 7 2023, Lisbon, Portugal), organized by Global Alliance. It provides main recommendations on how to best manage patients with advanced breast cancer (inoperable locally or metastatic), of all subtypes, as well palliative supportive care. These are based available evidence expert opinion when a higher level is lacking. Each guideline...
PURPOSE To compare giredestrant and physician's choice of endocrine monotherapy (PCET) for estrogen receptor–positive, HER2-negative, advanced breast cancer (BC) in the phase II acelERA BC study (ClinicalTrials.gov identifier: NCT04576455 ). METHODS Post-/pre-/perimenopausal women, or men, age 18 years older with measurable disease/evaluable bone lesions, whose disease progressed after 1-2 lines systemic therapy (≤1 targeted, ≤1 chemotherapy regimen, prior fulvestrant allowed) were randomly...